Introduction {#sec1}
============

Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a novel imaging modality that allows for molecular in vivo imaging of the retina and retinal pigment epithelium. FLIO may be able to distinguish different fluorophores or alteration of their environment by their fluorescence lifetime.[@bib1]^--^[@bib3] The technique is used in experimental diagnostic trials for various retinal diseases,[@bib4]^--^[@bib18] as well as in animal studies.[@bib19]^,^[@bib20] Its reproducibility has been validated in three studies, where the coefficient of variation was found to be below 20%.[@bib13]^,^[@bib21]^,^[@bib22] The technique is based on confocal scanning laser ophthalmoscopy, which greatly eliminates fluorescence light from the lens. However, the lens of the human eye shows extraordinarily strong fluorescence, especially in the case of cataract ([Fig. 1](#fig1){ref-type="fig"}), which arises from tryptophan as well as non-tryptophan peptides.[@bib23] Lens fluorescence increases with age[@bib24]^,^[@bib25] and, especially, with cataract[@bib23] or diabetes.[@bib26] With aging, post-translational protein changes take place; for example, tryptophan oxidation results in aromatic products with absorption and emission in the visible spectral range.[@bib23] Non-tryptophan fluorescence has been attributed to the insoluble protein fraction.[@bib27] In the aging lens, peptide fluorescence increases due to the formation of 3-hydroxykynurenine glucoside,[@bib28] 4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic acid,[@bib29] and glutathione-3-hydroxykynurenine glycoside.[@bib30] Thus, fluorescence measurements at the retina are likely influenced by a superimposition of the lens fluorescence. Because the fluorescence lifetime of the lens is longer than that measured from the retina and retinal pigment epithelium,[@bib1] increased mean lifetimes in FLIO readings in elderly patients[@bib13] might be skewed by lens fluorescence. For this reason, Klemm et al.[@bib31] introduced a layered components model for fitting fluorescence decays that makes use of the fact that the lens is anterior to the fundus, so fluorescence light from the lens will arrive at the detector earlier. Ideally, this should separate fluorescence components from the fundus and from the lens; however, this approach was never tested in a patient population. Thus, in this study, we analyzed FLIO readings of patients who underwent cataract surgery. As the fluorescence of the artificial intraocular lens can be assumed to be negligible ([Fig. 1](#fig1){ref-type="fig"}), the lifetimes of the postoperative measurements were assumed to be those of the fundus. This study aimed to understand changes in fluorescence lifetimes in cataracts. Measurements were done pre- and postoperatively, and various mathematical models were applied to identify a model that minimizes influence of the lens.

![Fluorescence intensity image of the anterior part of the eye of a 68-year-old patient before (*left*) and after (*right*) cataract extraction.](tvst-9-8-13-f001){#fig1}

Methods {#sec2}
=======

Patients {#sec2-1}
--------

Thirty-two patients (mean age, 72.3 years; SD, 9.3 years; range, 49--88 years) scheduled for cataract extraction were included in this study. Sixteen patients were female, and 16 were male. The study followed the tenets of the Declaration of Helsinki and was approved by a local ethics committee. Informed consent was obtained from all subjects before inclusion. All patients were diagnosed with cataracta provecta, and no distinction between nuclear or cortical cataract was made. Patients suffering from ophthalmic diseases other than cataract or from systemic diseases known to influence ocular fundus autofluorescence[@bib3] were excluded. Specifically, we excluded patients with age-related macular degeneration, cardiovascular disease (except well-controlled hypertension), macular telanciectasia, retinitis pigmentosa, retina vascular occlusions, hereditary retinal diseases such as Stargardt disease and choroideremia, central serous chorioretinopathy, Alzheimer\'s disease, or albinism. All investigations were performed 1 day before and on average 33.2 (± 10.3) days after cataract extraction.

Procedures {#sec2-2}
----------

All patients received a full ophthalmic investigation, including slit-lamp biomicroscopy, funduscopy, and measurement of intraocular pressure. The pupils were dilated using tropicamid (Mydriaticum Stulln, Pharma Stulln GmbH, Nabburg, Germany) and phenylephrinhydrochloride (Neosynephrin-POS 5%, Ursapharm GmbH, Saarbrucken, Germany). The patients then received FLIO imaging. In addition to the fundus FLIO, a recording of the fluorescence of the lens was taken. In order to standardize this measurement, the device was set at the maximum possible distance from the patient and focused onto the anterior part of the eye. At least 1000 photons per pixel were recorded, and the lifetimes were determined from a standardized square in the center of the lens. No sodium fluorescein was administered to the cornea or by intravenous injection prior to FLIO investigation. The basic principles and laser safety precautions for FLIO are described elsewhere.[@bib9]^,^[@bib13]^,^[@bib32] Briefly, a picosecond laser diode was coupled to a laser scanning ophthalmoscope (Spectralis; Heidelberg Engineering, Heidelberg, Germany) for autofluorescence excitation at 473 nm with a repetition rate of 80 MHz. Fluorescence photons were detected by time-correlated, single-photon counting (SPC-150 TCSPC Module; Becker & Hickl GmbH, Berlin, Germany) in a short-wavelength spectral channel (SSC, 498--560 nm) and a long-wavelength spectral channel (LSC, 560--720 nm). FLIO provides 30° images with a frame rate of 9 frames per second and a resolution of 256 × 256 pixels.

Models for the Approximation of Fluorescence Decays {#sec2-3}
---------------------------------------------------

For the approximation of lifetimes, we used FLIMX software,[@bib31] which is documented and freely available for download online under the open-source BSD license (<http://www.flimx.de>). Photon histograms over time, describing the autofluorescence decay, were least square fitted with a series of three exponential functions: $$I\left( t \right) = IRF*\sum\limits_{i\; = \; 1}^{3}a_{i} \cdot e^{- \frac{t}{\tau}_{i}}$$where *I*(*t*) is the fluorescence intensity at time *t*, *IRF* is the instrument response function of the device, *I*~0~ is the intensity at *t* = 0, τ*~i~* are the time constants of fluorescence decay, *a~i~* describe their abundance, and the asterisk denotes a convolution integral. This three-exponential fit of fluorescence decay is widely used in FLIO and is here denoted as model 0. The amplitude-weighted mean decay time (τ*~m~*) was used for further analysis, and the τ*~m~* of the postoperative measurements is considered the mean lifetime of the fundus. The relative contribution of each fluorescence component was defined by $$Q_{i} = \frac{a_{i} \cdot \tau_{i}}{\sum_{i}a_{i} \cdot \tau_{i}}$$

For the fit of the preoperative measurements, four different models, taking lens fluorescence into account, were investigated. Model 1: $$I\left( t \right) = IRF*\left( {a_{1} \cdot e^{- \frac{t}{\tau_{1}}} + a_{2} \cdot e^{- \frac{t}{\tau_{2}}} + a_{3} \cdot e^{- \frac{t - 150ps}{\tau_{3}\;}}} \right)$$was adopted from the suggestions of the SPC-150 TCSPC Module manufacturer, Becker & Hickl GmbH,[@bib33] and assumes two fluorescence components from the fundus, represented by the lifetimes τ~1~ and τ~2~, and one component from the lens (τ~3~), which is shifted against the fundus fluorescence by --150 ps. This is roughly the time it takes the light to travel the vitreous twice. Consequently, in this model, τ*~m~* is calculated from τ~1~ and τ~2~, weighted by *a*~1~ and *a*~2~ only. In order to be consistent with the postoperative analysis when using three lifetime components at the fundus, we also established and tested four-exponential models. Model 2: $$I\left( t\! \right)\, = \, IRF\,*\left( {{a_{1} \cdot \, e^{- \frac{t}{\tau_{1}}} + \, a_{2}\, \cdot \, e^{- \frac{t}{\tau_{2}}} + \, a_{3}\, \cdot \, e^{- \frac{t}{\tau_{3}}} + a_{4} \cdot \, e^{- \frac{t - 150ps}{\tau_{4}}}}\!} \right)$$assumes three components, τ~1~, τ~2~, and τ~3~, from which τ*~m~* is calculated, representing the fundus fluorescence, whereas the time-shifted τ~4~ represents the lens fluorescence. We do not know whether the lifetime of the lens or the slowest decay component from the fundus is larger; however, the software assumes τ~1~ \< τ~2~ \< τ~3~ \< τ~4~. Therefore, model 3: $$I\left( t\! \right)\, = \, IRF\,*\left( {\!{a_{1} \cdot \, e^{- \frac{t}{\tau_{1}}} + \, a_{2}\, \cdot \, e^{- \frac{t}{\tau_{2}}} + \, a_{3}\, \cdot e^{- \frac{t - 150ps}{\tau_{3}}} + \, a_{4} \cdot \, e^{- \frac{t}{\tau_{4}}}}} \right)$$was tested, where τ~3~ represents the time-shifted lens fluorescence and τ~4~ a very slow fundus fluorescence. Finally, we used the mean lifetime measured from the lens, instead of a free fitting parameter, as τ~3~ in [Equation 5](#equ5){ref-type="disp-formula"}, denoted as model 4. In models 3 and 4, τ*~m~* was calculated from τ~1~, τ~2~, and τ~4~ and the respective amplitudes. Fixating τ~4~ in [Equation 4](#equ4){ref-type="disp-formula"} to the lens lifetime resulted in poor fits (data not shown). Thus, this approach was not pursued further.

For all approximations, τ*~m~* was averaged over the central area, the inner and outer ring, and the whole field of the standardized Early Treatment Diabetic Retinopathy Study (ETDRS) grid. These values were compared for all fits (models 0 through 4) of the preoperative measurements with those of the postoperative measurements (model 0) in paired *t*-tests using SPSS Statistics 26 (IBM, Armonk, NY, USA). Furthermore, Spearman correlation coefficients were determined. In order to obtain an estimate of the relative contribution of lens fluorescence to total fluorescence, the *Q* value of the shifted fluorescence component was calculated. This is the product of the respective *a* and τ values (e.g., *a*~3~ and τ~3~ for model 1, *a*~4~ and τ~4~ for model 2) normalized to the total fluorescence.

Results {#sec3}
=======

One patient had to be excluded because the cataract was too dense to obtain a preoperative FLIO measurement of the fundus. [Figure 2](#fig2){ref-type="fig"} shows an example of color-coded τ*~m~* from the postoperative measurement, as well as models 0 through 4 applied to the preoperative measurement in both spectral channels. Because the color-coding is the same for all panels per channel, this figure clearly demonstrates the overestimation of the fluorescence lifetime due to including all fluorescence components in the calculation of τ*~m~* (compare postoperative and model 0 panels). This particularly holds true for the SSC. In contrast, models 1 and 2 showed fit results similar to the postoperative results, although those of model 2 are noisier. The lifetimes, given by models 3 and 4, are considerably longer than the postoperatively measured lifetimes. Despite these differences in the results, all models were able to fit the measured decays well. [Supplementary Figure S2](#tvst-9-8-13_s001){ref-type="supplementary-material"} shows the decay curve along with model fit for a 100 × 100 pixel from one patient; the residuals of the fit are plotted at the bottom of each panel.

![FLIO images of a 71-year-old subject. (*Top row, left to right*) SSC: fluorescence intensity postoperative, mean lifetime τ*~m~* postoperative, τ*~m~* preoperative model 0, and τ*~m~* preoperative model 1. (*Second row, left to right*) SSC: τ*~m~* preoperative model 2, τ*~m~* preoperative model 3, and τ*~m~* preoperative model 4. Color-coding of lifetimes is identical (50--350 ps) for all panels in the first two rows. (*Third row, left to right*) LSC: fluorescence intensity postoperative, τ*~m~* postoperative, τ*~m~* preoperative model 0, and τ*~m~* preoperative model 1. (*Bottom* *row, left to right*) LSC: τ*~m~* preoperative model 2, τ*~m~* preoperative model 3, and τ*~m~* preoperative model 4. Color-coding of lifetimes is identical (50--400 ps) for all panels in the last two rows. Images are scaled in pixels; the size of 1 pixel is 35 × 35 µm^2^ in an emmetropic eye. The preoperative fluorescence intensity image in SSC is shown in [Supplementary Figure S1](#tvst-9-8-13_s001){ref-type="supplementary-material"}.](tvst-9-8-13-f002){#fig2}

The mean values of τ*~m~* over all 31 patients are shown in [Table 1](#tbl1){ref-type="table"} for the postoperative FLIO measurements (model 0), as well as for the preoperative measurements (models 0 through 4; see [Supplementary Tables S1](#tvst-9-8-13_s001){ref-type="supplementary-material"} and [S2](#tvst-9-8-13_s001){ref-type="supplementary-material"} for single lifetime components τ~1~ through τ~4~ and their relative amplitudes, *a*~1~ through *a*~4~). *P* values for the paired comparisons of the postoperative data with the respective model fits of the preoperative measurements are also given. In all regions of the ETDRS grid, the three-exponential fit (model 0) resulted in considerably longer τ*~m~* values for the preoperative measurements than for the postoperative ones. Also, τ*~m~* values for models 3 and 4, assuming a shifted third fluorescence component from the lens, greatly deviate from the postoperative results ([Table 1](#tbl1){ref-type="table"}). Thus, in the following, we focus on models 1 and 2, applying lens fluorescence to the longest living decay component. The application of these models is shown in [Figure 3](#fig3){ref-type="fig"} for three more cases.

###### 

Mean Values (SD) Over All Subjects for Mean Lifetime τ*~m~* (ps)[^\*^](#tb1fn1){ref-type="table-fn"}

                  Center Circle   *P*       Inner Ring   *P*       Outer Ring   *P*       Full Circle   *P*
  --------------- --------------- --------- ------------ --------- ------------ --------- ------------- ---------
  SSC                                                                                                   
  Postoperative   109 (25)                  171 (23)               192 (24)               185 (22)      
   Model 0        491 (195)       \<0.001   480 (224)    \<0.001   474 (200)    \<0.001   474 (206)     \<0.001
   Model 1        135 (44)        \<0.001   189 (45)     0.014     210 (46)     0.02      203 (45)      0.017
   Model 2        134 (47)        0.001     187 (50)     0.046     209 (51)     0.043     202 (50)      0.04
   Model 3        297 (184)       \<0.001   351 (189)    \<0.001   344 (160)    \<0.001   344 (167)     \<0.001
   Model 4        287 (147)       \<0.001   339 (145)    \<0.001   344 (129)    \<0.001   341 (133)     \<0.001
  LSC                                                                                                   
  Postoperative   146(30)                   196 (33)               216 (35)               209 (34)      
   Model 0        266(97)         \<0.001   293 (75)     \<0.001   300 (67)     \<0.001   298 (69)      \<0.001
   Model 1        151(33)         0.285     202 (29)     0.183     222 (30)     0.175     215 (29)      0.175
   Model 2        117(37)         \<0.001   161 (47)     \<0.001   182 (51)     \<0.001   175 (49)      \<0.001
   Model 3        227(78)         \<0.001   243 (68)     0.001     247 (64)     0.019     245 (64)      0.007
   Model 4        212(50)         \<0.001   246 (53)     \<0.001   255 (54)     \<0.001   252 (53)      \<0.001

^\*^From the postoperative three-exponential fit (model 0) and preoperative fits according to models 0 to 4, as well as *P* values for the paired *t*-tests of the pre- versus postoperative fits in the center, inner, and outer ring and full circle of the ETDRS grid. Bonferroni correction for multiple testing was applied to the *P* values.

![FLIO images (SSC) of subjects who were 74 years old (*top row*), 77 years old (*middle row*), and 80 years old (*bottom row*). (*Left to right*) Mean lifetime τ*~m~* postoperative, τ*~m~* preoperative model 0, τ*~m~* preoperative model 1, and τ*~m~* preoperative model 2. Color-coding is scaled identically for all models per subject as indicated (50--450 ps, 50--500 ps, and 50--400 ps, respectively). Images are scaled in pixels; the size of 1 pixel is 35 × 35 µm^2^ in an emmetropic eye.](tvst-9-8-13-f003){#fig3}

The relative contributions of the third (*Q*~3~ in model 1) and fourth (*Q*~4~ in model 2) fluorescence components consistently indicated a considerable amount of total fluorescence: *Q*~3~ values were 54.2 ± 10.6% (SSC) and 29.5 ± 9.9% (LSC), and *Q*~4~ values were 52.6 ± 11.1% (SSC) and 25.2 ± 11.2% (LSC), all measured in the full circle of the ETDRS grid. Mean lifetimes of the lens, measured from FLIO images of the anterior part of the eye, were 2813 ± 349 ps (SSC) and 1951 ± 252 ps (LSC).

Furthermore, we explored the correlations between pre- and postoperative τ*~m~* ([Table 2](#tbl2){ref-type="table"}). These are shown in [Figure 4](#fig4){ref-type="fig"} for the full circle of the ETDRS grid. The figure also shows only minor differences between model 1 and model 2. The differences between postoperative measurements and models 1 and 2 for preoperative measurements are shown in Bland--Altman plots ([Fig. 4](#fig4){ref-type="fig"}). The absolute values of the differences for the full circle were 32 and 36 ps (SSC, models 1 and 2) and 20 and 42 ps (LSC, models 1 and 2), on average. These values were smaller than the respective standard deviations of the inter-individual variances: 45 and 50 ps (SSC, models 1 and 2) and 29 and 49 ps (LSC, models 1 and 2).

###### 

Pearson Correlation Coefficients (*R*^2^) and Respective *P* Values Describing the Association of Postoperative τ*~m~* with Preoperative Fits According to Models 1 and 2 in the Center, Inner, and Outer Ring and Full Circle of the ETDRS Grid

             Center Circle   *P*       Inner Ring   *P*       Outer Ring   *P*       Full Circle   *P*
  ---------- --------------- --------- ------------ --------- ------------ --------- ------------- ---------
  SSC                                                                                              
   Model 1   0.339           \<0.001   0.320        \<0.001   0.187        0.015     0.203         0.011
   Model 2   0.324           \<0.001   0.320        \<0.001   0.176        0.019     0.201         0.012
  LSC                                                                                              
   Model 1   0.507           \<0.001   0.471        \<0.001   0.561        \<0.001   0.528         \<0.001
   Model 2   0.258           0.04      0.208        0.01      0.202        0.011     0.198         0.012

![Correlation between postoperative and preoperative (models 1 and 2) mean lifetimes (τ*~m~*) in the SSC (*top left*) and LSC (*top right*) for the full circle of the ETDRS grid along with Bland--Altman plots of the differences of τ*~m~* between both preoperative models and the postoperative measurement for the SSC (*middle*) and LSC (*bottom*). Dashed lines indicate 95% confidence intervals for the limits of agreement.](tvst-9-8-13-f004){#fig4}

Discussion {#sec4}
==========

Lens fluorescence considerably influences fluorescence lifetimes measured at the retina by FLIO. This is reflected by the more than 2.5-times longer lifetimes (SSC full circle; see [Table 1](#tbl1){ref-type="table"} and [Fig. 2](#fig2){ref-type="fig"}) for model 0 compared to the postoperative measurements. As the same fit models were used, this difference has to be attributed to the lens. Even in non-cataract eyes, lens fluorescence seems to influence the fundus FLIO readings in an age-dependent manner. Dysli et al.[@bib13] showed an increase of τ*~m~* with age in healthy subjects. Because this increase was larger for the non-dilated than for the dilated pupil, these authors argued that the age dependence of the lifetimes, at least partially, could result from lens fluorescence. Here, we were able to quantify the influence of the cataract lens to fundus FLIO measurements. Fitting the preoperative measurements with the three-exponential decay model (model 0), which is used in most publications, resulted in an overestimation of the lifetimes (τ*~m~*) by 320 ps (173%) in the SSC and by 100 ps (48%) in the LSC, as is apparent from the comparison with postoperative measurements in the full ETDRS grid. For the macula, this overestimation is even higher ([Table 1](#tbl1){ref-type="table"}). This overestimation clearly results from the fluorescence of the cataract lens, which contributed to the total measured fluorescence by 5% to 55% in the SSC and by 25% to 30% in the LSC, as indicated by *Q*~3~ and *Q*~4~ in models 1 and 2, respectively. This raises an urgent need to compensate for lens fluorescence. This could be achieved by changing the optical setup by introducing an aperture diaphragm separation, as suggested by Klemm et al.[@bib34] Because such a change has not been implemented in the FLIO device, we relied on the temporal anteriority of the lens fluorescence compared to that of the fundus. This can be observed as a step-shaped distortion of the rising edge of the fluorescence.[@bib31] Because the width of the instrument response function of the FLIO device is on the order of the time difference between lens and fundus fluorescence, this step is difficult to detect in conventional FLIO but was more clearly demonstrated by Becker et al.[@bib33] using an ultra-fast detector. However, the time shift of lens fluorescence can also be derived from data obtained with the FLIO device currently used in clinical investigations.[@bib31] Accordingly, this approach was tested by Becker et al.[@bib33] on one subject using a three-exponential model with one shifted component (model 1). We expanded this approach to more decay models and tested them in a cohort of 31 patients, large enough to obtain statistically reliable results.

Models 3 and 4 failed, as they were not able to reproduce the postoperative mean fluorescence lifetimes assumed to be the ground truth of ocular fundus fluorescence. Model 1 resulted in mean values of τ*~m~* that were closest to those of the postoperative measurements for all fields of the ETDRS grid ([Table 1](#tbl1){ref-type="table"}). Furthermore, τ*~m~* values from model 1 showed the highest correlation coefficients with the postoperative τ*~m~* values ([Table 2](#tbl2){ref-type="table"}). Agreement between model 1 and the postoperative measurements was better for the LSC than for the SSC. This is reasonable, because the lens emits fluorescence in the blue and green spectral range.[@bib23]^,^[@bib30] Thus, the LSC (above 560 nm) is less disturbed by lens fluorescence. This is further supported by the fact that the deviation of model 0 from the postoperative data is much more pronounced in the SSC than in the LSC. However, it must be noted that the correlation between the results from model 1 and the postoperative measurements is weak (SSC, *R*^2^ = 0.203; LSC, *R*^2^ = 0.528) ([Fig. 4](#fig4){ref-type="fig"}). This means that the compensation for lens fluorescence by model 1 did not work equally well in all patients. Nevertheless, deviations of the pre- and postoperative measurements are much lower with the correction (model 1) than without (model 0). The correction in model 1 resulted in τ*~m~* values for which differences from postoperative measures were below the standard deviations of the inter-individual variances ([Fig. 4](#fig4){ref-type="fig"}, Bland--Altman plots).

Model 2 worked as well as model 1 for the SSC (see data in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}) but was inferior for the LSC. From a theoretical point of view, however, model 2 should be favored. Consistent with the fits of the postoperative measurements, model 2 assumes three decay components for the fundus fluorescence, and the non-zero *a*~3~, found in pseudophakic eyes, indicates that there is a slow-decaying fluorescence component from the fundus. One reason for the potential superiority of model 1 might be the higher numerical stability of fit, as it uses six free parameters and model 2 has to determine eight parameters ([Equations 3](#equ3){ref-type="disp-formula"} and [4](#equ4){ref-type="disp-formula"}). Also, the τ*~m~* values for models 1 and 2 were strongly correlated (for the full circle, *R*^2^ = 0.98 for the SSC and *R*^2^ = 0.92 for the LSC), so model 1 can be assumed to give a good estimate of the fundus fluorescence lifetimes in cataract eyes.

Just by its design, this study has some limitations. The main limitation is its restriction to cataract patients. This was necessary in order to utilize postoperative reference values; with the current optics of the FLIO device, it is impossible to measure the fundus fluorescence without perturbation of that of the lens in phakic eyes. This, however, restricts the preference for model 1, supported by our data, to cataract eyes. We cannot say whether this also holds true for non-cataract eyes or if another model would be more appropriate. Furthermore, although the fit according to model 1 works very well on average, deviations in single subjects were remarkable. In this study, we did not differentiate among the various kinds and severity levels of cataracts, as our study population was too small for the investigation of subgroups. Thus, we cannot tell whether abovementioned deviations are related to cataract type or severity.

In conclusion, we were able to show that lens fluorescence contributes considerably to the FLIO signal and greatly alters the measured fundus fluorescence lifetimes. However, a mean fluorescence lifetime (τ*~m~*), calculated as the amplitude-weighted average of τ~1~ and τ~2~ from a three-exponential fit of the measurements in which τ~3~ was temporally shifted and assumed to represent lens fluorescence (model 1), was close to the fundus lifetime measured in the same eyes after cataract extraction, on average. Future experiments should investigate factors influencing individual cataract effects, as well as the applicability of this model to eyes without cataract.
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